Zacks Research Upgrades Hyperion DeFi (NASDAQ:HYPD) to Hold

Hyperion DeFi (NASDAQ:HYPD) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other analysts have also issued reports about the stock. Chardan Capital lowered their price target on shares of Hyperion DeFi from $8.25 to $7.30 and set a “buy” rating on the stock in a research report on Monday, June 8th. Cantor Fitzgerald lifted their price objective on Hyperion DeFi from $4.00 to $6.60 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Finally, Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Hyperion DeFi presently has a consensus rating of “Hold” and a consensus target price of $6.95.

Hyperion DeFi Price Performance

Hyperion DeFi stock opened at $3.02 on Tuesday. Hyperion DeFi has a 52 week low of $2.49 and a 52 week high of $16.12. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $3.30 and its 200 day simple moving average is $3.47. The firm has a market capitalization of $45.78 million, a PE ratio of -0.30 and a beta of 2.49.

Insider Activity at Hyperion DeFi

In other news, insider Hyunsu Jung acquired 7,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average price of $3.70 per share, with a total value of $25,900.00. Following the completion of the transaction, the insider directly owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This represents a 0.51% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.50% of the stock is currently owned by company insiders.

Institutional Trading of Hyperion DeFi

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sanctuary Advisors LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter worth $38,000. Nations Financial Group Inc. IA ADV purchased a new position in Hyperion DeFi during the fourth quarter worth about $40,000. Price T Rowe Associates Inc. MD purchased a new position in Hyperion DeFi during the fourth quarter worth about $73,000. Formidable Asset Management LLC purchased a new position in Hyperion DeFi during the fourth quarter worth about $83,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi in the 4th quarter worth about $92,000. 25.84% of the stock is owned by hedge funds and other institutional investors.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.